"Strong financial performance and launch of Brixadi(TM) in the US"
Third quarter summary 2023
July - September
- Total revenues amounted to
SEK 384 (241) million, an increase of 59% (49% at CER1), whereof product sales wereSEK 346 (241) million, an increase of 44% (38% at CER1) - Compared to previous quarter, product sales increased 13% (9% at CER1)
-
Operating result was
SEK 104 (41) million, an increase ofSEK 63 million (154%) -
Cash position at the end of the quarter was
SEK 1,154 (520) million, an increase ofSEK 634 million (122%) - Number of patients treated with Buvidal® increased to approximately 45,000
-
The
European Commission issued continued marketing authorization for Buvidal with unlimited validity - Brixadi(TM) launched for the treatment of patients with opioid use disorder (OUD) in the US
Camurus receivedUSD 35 million from Braeburn as a one-time payment for the US approval of Brixadi- Positive results were announced from the long-term Phase 3 study of CAM2029 in patients with acromegaly
- Publication of population pharmacokinetic analyses of Buvidal in Clinical Pharmacokinetics2
January - September
- Total revenues amounted to
SEK 1,342 (688) million, an increase of 95% (86% at CER1), whereof product sales wereSEK 933 (668) million, an increase of 40% (35% at CER1) -
Operating result was
SEK 554 (53) million, an increase ofSEK 501 million (945%)
Significant events after the period
- Financial outlook for full year 2023 revenue was raised from
SEK 1,530 - 1,650 million toSEK 1,640 - 1,720 million and profit before taxes fromSEK 425 - 525 million toSEK 525 - 600 million
Financial summary third quarter 2023
- Total revenue
SEK 384 (241) million
- whereof product salesSEK 346 (241) million -
OPEX
SEK 253 (184) million -
Operating result
SEK 104 (41) million -
Result for the period
SEK 86 (35) million -
Earnings per share after dilution, of
SEK 1.50 (0.61) -
Cash position
SEK 1,154 (520) million
1. At constant exchange rates
2. Björnsson, M., et al. Clin Pharmacokinet. 2023;62:1427-1443
"
Audiocast
Financial analysts and media are invited to attend a telephone conference and presentation of the results today at
For more information:
Tel. +46 (0)46 286 46 92
fredrik.tiberg@camurus.com
Fredrik Joabsson, Chief Business Development Officer
Tel. +46 (0)70 776 17 37
ir@camurus.com
About
This information is information that
https://news.cision.com/camurus-ab/r/camurus--interim-report-third-quarter-2023,c3872202
https://mb.cision.com/Main/13456/3872202/2417818.pdf
(c) 2023 Cision. All rights reserved., source